What Are Signs of Too Much or Too Little Steroid in CAH?
At a Glance
Too little steroid in a child with CAH may cause rapid growth, early puberty, salt-wasting symptoms, or adrenal crisis during illness; too much may slow growth, cause weight gain, or raise blood pressure. An endocrinologist must use tests and growth trends before changing treatment.
In this answer
3 sections
Finding the right steroid dose for a child with classic congenital adrenal hyperplasia (CAH) is a delicate balancing act. If the glucocorticoid (hydrocortisone) dose is too low, the adrenal glands overproduce androgens (hormones present in all people, but which can cause early or virilizing physical changes in children when produced in excess). This can lead to early puberty and rapid, but ultimately limited, growth. Conversely, if the steroid dose is too high, it can slow down growth and cause unhealthy weight gain.
Because children grow and their needs change, knowing the physical signs of undertreatment and overtreatment can help you monitor your child’s health at home between doctor appointments [1]. However, you should never adjust your child’s daily maintenance dose based on these physical signs alone.
🚨 Emergency Warning: Adrenal Crisis
An adrenal crisis is a life-threatening emergency [2]. While inadequate daily steroid doses can leave a child vulnerable, a crisis most often occurs when a child is sick (fever, infection, vomiting, surgery) and their body needs more cortisol than usual [3].
- Signs of a Crisis: Repeated vomiting, severe weakness, unusual sleepiness, confusion, fainting, or severe dehydration [4][2].
- Action Required: Do not wait for an appointment or lab results. Follow your endocrinologist’s written sick-day plan immediately by giving prescribed stress-dose hydrocortisone. If your child cannot keep oral medication down, administer their emergency hydrocortisone injection and seek urgent emergency medical care [3].
Signs of Undertreatment (Too Little Steroid)
Glucocorticoid (Hydrocortisone) Undertreatment
When a child is not getting enough hydrocortisone, their body produces excess adrenal androgens [5]. This can cause several noticeable physical changes:
- Rapid Growth and Advanced Bone Age: Your child might seem to be growing much faster than their peers [6]. However, untreated androgen excess causes the growth plates in their bones to mature and close too early, which can severely reduce their final adult height [7].
- Early Puberty and Virilization: You may notice rapidly progressive or unusually early changes such as pubic or underarm hair, severe acne, deepening of the voice, or adult body odor [8][9]. Mention any new or rapid changes to your endocrinology team.
Mineralocorticoid (Fludrocortisone) Undertreatment
Children with the salt-wasting form of CAH need mineralocorticoid (fludrocortisone) treatment to help their bodies retain sodium (salt). If the dose is too low, they may experience:
Signs of Overtreatment (Too Much Steroid)
Glucocorticoid (Hydrocortisone) Overtreatment
While higher doses suppress excess androgens, chronic over-replacement of glucocorticoids mimics a condition called Cushing’s syndrome [11]:
- Poor Height Gain: Excess glucocorticoids suppress a child’s natural growth rate, leading to lower-than-expected height gain over time [12].
- Rapid Weight Gain: Overtreatment often causes rapid weight gain and a higher body mass index (BMI) [12]. You might notice fat accumulating primarily around the belly or the face, resulting in a rounded or “cushingoid” appearance [13].
- Bone Health Concerns: Long-term exposure to high doses of glucocorticoids is a risk factor for decreased bone mineral density (the thickness and strength of bones) later in life [14].
Mineralocorticoid (Fludrocortisone) Overtreatment
- High Blood Pressure: Too much fludrocortisone can cause fluid retention and elevated blood pressure (hypertension) [15].
The Importance of Comprehensive Monitoring
You should not adjust maintenance doses based on physical changes. Some physical signs—like a drop in growth velocity—take months to become noticeable [16].
To safely manage CAH, endocrinologists use a combination of tools:
- Scheduled Blood Tests: Labs measuring hormones (like 17-OHP and androstenedione) and electrolytes (sodium and potassium) or renin (a hormone that helps control blood pressure) act as snapshots [17]. They help identify biochemical trends before physical changes become obvious.
- No Single “Perfect” Number: Results depend heavily on when the blood was drawn relative to the last medication dose [17]. For example, 17-OHP is not normally expected to be completely zero in a well-treated child, as excessive suppression indicates glucocorticoid overtreatment [18].
- The Big Picture: Clinicians interpret labs together with growth trends, weight, blood pressure, physical exams, and occasionally bone age (an X-ray of the hand to check growth plate maturation) [1].
Keeping a practical home log—recording medication times, missed or vomited doses, sick days, stress doses, and weight trends—gives your care team the necessary context to safely adjust your child’s treatment [1].
Common questions in this guide
How can I tell if my child is receiving too little hydrocortisone for CAH?
What might too much hydrocortisone look like in a child with CAH?
What are signs that my child may need more fludrocortisone?
Can too much fludrocortisone cause symptoms?
When should I worry about an adrenal crisis?
Should I change my child's daily steroid dose when I see these signs?
How do doctors check whether CAH treatment is balanced?
Related questions
Show more
Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence
Peltek Kendirci HN, Ünal E, Dündar İ, et al.
Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.
PMID: 39713876 - 2
Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany.
Dörr HG, Wollmann HA, Hauffa BP, et al.
BMC endocrine disorders 2018; (18(1)):37 doi:10.1186/s12902-018-0263-1.
PMID: 29884168 - 3
Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life.
Odenwald B, Nennstiel-Ratzel U, Dörr HG, et al.
European journal of endocrinology 2016; (174(2)):177-86 doi:10.1530/EJE-15-0775.
PMID: 26563979 - 4
[Clinical and genetic characteristics of 165 children with salt-wasting 21-hydroxylase deficiency in Henan Province].
Yang HH, Huang A, Li Y, et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2026; (28(4)):480-485 doi:10.7499/j.issn.1008-8830.2506116.
PMID: 42015704 - 5
Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia.
Kamrath C, Hartmann MF, Pons-Kühnemann J, Wudy SA
Metabolism: clinical and experimental 2020; (112()):154354 doi:10.1016/j.metabol.2020.154354.
PMID: 32916150 - 6
Growth curves for congenital adrenal hyperplasia from a national retrospective cohort.
Bretones P, Riche B, Pichot E, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(12)):1379-1388.
PMID: 27852974 - 7
Growth and development in children with classic congenital adrenal hyperplasia.
Bonfig W
Current opinion in endocrinology, diabetes, and obesity 2017; (24(1)):39-42 doi:10.1097/MED.0000000000000308.
PMID: 27898585 - 8
Non-PCOS Hyperandrogenic Disorders in Adolescents.
Esquivel-Zuniga MR, Kirschner CK, McCartney CR, Burt Solorzano CM
Seminars in reproductive medicine 2022; (40(1-02)):42-52 doi:10.1055/s-0041-1742259.
PMID: 35052005 - 9
Congenital Adrenal Hyperplasia.
Fraga NR, Minaeian N, Kim MS
Pediatrics in review 2024; (45(2)):74-84 doi:10.1542/pir.2022-005617.
PMID: 38296783 - 10
Congenital adrenal hyperplasia with salt-wasting crisis and arrhythmia: a case study.
Canlas JF, Ponmani C
BMJ case reports 2019; (12(1)) doi:10.1136/bcr-2018-227565.
PMID: 30700462 - 11
[Steroid 21-hydroxylase deficiency, the most frequent cause of congenital adrenal hyperplasia].
Doleschall M, Török D, Mészáros K, et al.
Orvosi hetilap 2018; (159(7)):269-277 doi:10.1556/650.2018.30986.
PMID: 29429350 - 12
The urinary steroidome of treated children with classic 21-hydroxylase deficiency.
Kamrath C, Wettstaedt L, Boettcher C, et al.
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt B)):396-406 doi:10.1016/j.jsbmb.2016.08.006.
PMID: 27544322 - 13
Growth Assessment and Nutritional Status in Children with Congenital Adrenal Hyperplasia-A Cross-Sectional Study from a Vietnamese Tertiary Pediatric Center.
Nguyen TTH, Le KM, Tran TAT, et al.
Diagnostics (Basel, Switzerland) 2025; (15(12)) doi:10.3390/diagnostics15121534.
PMID: 40564853 - 14
Clinical Manifestations and Challenges in Adolescent and Adult Females With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
Engberg H, Nordenström A, Hirschberg AL
The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S37-S45 doi:10.1210/clinem/dgae696.
PMID: 39836618 - 15
The role of renin, fludrocortisone, and hypertension in early childhood in patients with congenital adrenal hyperplasia.
Chin X, van der Meijden JC, van Herwaarden AE, Claahsen-van der Grinten HL
European journal of endocrinology 2026; (195(2)):271-280 doi:10.1093/ejendo/lvag146.
PMID: 42554593 - 16
Monitoring treatment in pediatric patients with 21-hydroxylase deficiency.
Itonaga T, Hasegawa Y
Frontiers in endocrinology 2023; (14()):1102741 doi:10.3389/fendo.2023.1102741.
PMID: 36843618 - 17
An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.
Al-Kofahi M, Ahmed MA, Jaber MM, et al.
British journal of clinical pharmacology 2021; (87(3)):1098-1110 doi:10.1111/bcp.14470.
PMID: 32652643 - 18
Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management.
Sarafoglou K, Merke DP, Reisch N, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(9)):2154-2175 doi:10.1210/clinem/dgad134.
PMID: 36950738
This page is for informational purposes only and does not constitute medical advice or replace your child's endocrinology team's instructions. Do not change maintenance steroid doses based on signs alone, and follow the written emergency plan for possible adrenal crisis.